DNA Chat (Mendly Care)
About
DNA Chat developed Mendly Care, the first virtual care/telemedicine platform integrating AI symptom triage, full-genome sequencing, and secure DNA storage. Americans with rare genetic conditions spend an average of 6 years and $116,500 before correct diagnosis. Mendly sequences genomes for $400 using patented DNA Hyper-Sharding technology.
AI Investment Summary
Mendly Care combines telemedicine with full-genome sequencing at $400/genome. The precision medicine market is $73B+ and growing. Early stage with $5M valuation makes this high-risk but potentially transformative.
Structure
Direct Equity
Stage
Seed
Accreditation
Open to All
Liquidity
Illiquid
Geography
United States
Revenue
pre revenue
Funding Progress
25%Total Investors
300
Green Flags
- $73B+ precision medicine market
- Patented DNA Hyper-Sharding technology
- $400/genome is significantly below competitors
- AI symptom triage differentiator
Risk Flags
- Pre-revenue with $5M valuation
- FDA regulatory pathway for genomic diagnostics
- Competitive telehealth market
- Consumer adoption of genetic testing varies
Similar Deals in Healthcare
Breath Diagnostics
Seed
Detecting diseases with a single breath — non-invasive diagnostics.
Min. Investment
$100
NeuralMed
Series A
FDA-cleared AI cancer detection — 97% accuracy, deployed at 45 hospitals.
Min. Investment
$250
Funded
64%
Vybe Medical
Series A
AI-assisted mental health platform — $65/session, 25K patients.
Min. Investment
$200
Funded
58%
Minimum Investment
$100
Valuation
$5M
Lock-up Period
5 years (until exit)
Tags
LISTED
2026-02-01